We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02767804




Registration number
NCT02767804
Ethics application status
Date submitted
30/04/2016
Date registered
10/05/2016
Date last updated
29/01/2021

Titles & IDs
Public title
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Scientific title
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Secondary ID [1] 0 0
X396-CLI-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - X-396 (ensartinib)
Treatment: Drugs - crizotinib

Experimental: X-396 (ensartinib) - Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops

Active Comparator: crizotinib - Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops


Treatment: Drugs: X-396 (ensartinib)
oral ALK inhibitor

Treatment: Drugs: crizotinib
oral ALK inhibitor

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) as assessed by independent radiology review based on RECIST v. 1.1 criteria
Timepoint [1] 0 0
36 months
Secondary outcome [1] 0 0
Overall survival (OS)
Timepoint [1] 0 0
48 months
Secondary outcome [2] 0 0
CNS response rate based on independent radiology review
Timepoint [2] 0 0
36 months
Secondary outcome [3] 0 0
Time to CNS progression based on independent radiology review
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
ORR based on independent radiology review
Timepoint [4] 0 0
36 months

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage
IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is
ALK-positive by an FDA-approved assay performed centrally. Patients must be ALK
positive by local test prior to submitting tissue to the central lab. Randomization
will occur after ALK positive confirmation is received from the central lab. Patients
may have received up to 1 prior chemotherapy regimen for metastatic disease, which may
also include maintenance therapy. Note that patients that have received adjuvant or
neoadjuvant chemotherapy and developed metastatic disease within 6 months from the end
of that therapy would be considered to have received 1 prior regimen for metastatic
disease.

2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.
(see Appendix A)

3. Life expectancy of at least 12 weeks.

4. Ability to swallow and retain oral medication.

5. Adequate organ system function, defined as follows:

1. Absolute neutrophil count (ANC) =1.5 x 109/L

2. Platelets =100 x 109/L

3. Hemoglobin =9 g/dL (=90 g/L) Note that transfusions are allowed to meet the
required hemoglobin level

4. Total bilirubin =1.5 times the upper limit of normal (ULN)

5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 x ULN if
no liver involvement or =5 x ULN with liver involvement.

6. Creatinine < 1.5 x ULN. If >1.5 x ULN, patient may still be eligible if
calculated creatinine clearance >50 mL/min (0.83mL/s) as calculated by the
Cockcroft-Gault method.

6. Brain metastases allowed if asymptomatic at study baseline. Patients with untreated
brain metastases must not be on corticosteroids. If patients have neurological
symptoms or signs due to CNS metastases, patients need to complete whole brain
radiation or focal treatment at least 14 days before start of study treatment and be
asymptomatic on stable or decreasing doses of corticosteroids at baseline.

7. Men with partners of childbearing potential willing to use adequate contraceptive
measures during the study and for 90 days after the last dose of study medication.

8. Women who are not of child-bearing potential, and women of child-bearing potential who
agree to use adequate contraceptive measures during the study and for 90 days after
the last dose of study medication, and who have a negative serum or urine pregnancy
test within 1 week prior to initial trial treatment.

9. Patients must be >18 years-of-age.

10. Patients must have measurable disease per RECIST v. 1.1.

11. Willingness and ability to comply with the trial and follow-up procedures.

12. Ability to understand the nature of this trial and give written informed consent.

Note the following pertains to patients enrolled in France

In France, a subject will be eligible for inclusion in this study only affiliated to the
French Social Security system, and currently benefit from the corresponding rights and
cover.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Patients that have previously received an ALK TKI or PD-1/PD-L1 therapy, and patients
currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy,
radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or
tumor embolization).

2. Use of an investigational drug within 21 days prior to the first dose of study drug.
Note that to be eligible, any drug-related toxicity should have recovered to Grade 1
or less, with the exception of alopecia.

3. Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14
days.

4. Patients with primary CNS tumors and leptomeningeal disease are ineligible.

5. Patients with a previous malignancy within the past 3 years (other than curatively
treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any
cancer that is considered to be cured and have no impact on PFS and OS for the current
NSCLC).

6. Concomitant systemic use of anticancer herbal medications. These should be stopped
prior to study entry.

7. Patients receiving

1. strong CYP3A inhibitors (including, but not limited to, atazanavir,
clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,
ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit,
grapefruit juice)

2. strong CYP3A inducers (including, but not limited to, carbamazepine,
phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort)

3. CYP3A substrates with narrow therapeutic window (including, but not limited to,
alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,
quinidine, sirolimus, tacrolimus).

8. Women who are pregnant or breastfeeding.

9. Presence of active gastrointestinal (GI) disease or other condition that will
interfere significantly with the absorption, distribution, metabolism, or excretion of
study medications.

10. Patients at risk for GI perforation.

11. Clinically significant cardiovascular disease including:

1. QTcF interval >450 ms for men and >470 ms for women, symptomatic bradycardia <45
beats per minute or other significant ECG abnormalities in the investigator's
opinion.

2. Clinically uncontrolled hypertension in the investigator's opinion (e.g., blood
pressure >160/100 mmHg; note that isolated elevated readings considered to not be
indicative of uncontrolled hypertension are allowed).

The following within 6 months prior to Cycle 1 Day 1:

1. Congestive heart failure (New York Heart Class III or IV).

2. Arrhythmia or conduction abnormality requiring medication. Note: patients with
atrial fibrillation/flutter controlled by medication and arrhythmias controlled
by pacemakers are eligible.

3. Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial
infarction.

4. Cerebrovascular accident or transient ischemia.

12. Patients who are immunosuppressed (including known HIV infection), have a serious
active infection at the time of treatment, have interstitial lung disease/pneumonitis,
or have any serious underlying medical condition that would impair the ability of the
patient to receive protocol treatment. Patients with controlled hepatitis C, in the
investigator's opinion, are allowed. Patients with known hepatitis B must be HBeAg and
HB viral DNA negative for enrollment. Note that, because of the high prevalence, all
patients in the Asia-Pacific region (except Australia, New Zealand, and Japan) must be
tested and, if HBsAg positive, must be HBeAg and HB viral DNA negative for enrollment.

13. Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.

14. Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.

15. Concurrent condition that in the investigator's opinion would jeopardize compliance
with the protocol or would impart excessive risk associated with study participation
that would make it inappropriate for the patient to be enrolled.

16. Inability or unwillingness to comply with study and/or follow-up procedures outlined
in the protocol.

Note the following pertains to patients enrolled in France

17. In France, a subject will not be eligible when under legal protection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Border Medical Oncology Research Unit - Albury
Recruitment hospital [2] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Chris O Brien Lifehouse - Camperdown
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
- Camperdown
Recruitment postcode(s) [3] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Hawaii
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Argentina
State/province [14] 0 0
Buenos Aires
Country [15] 0 0
Argentina
State/province [15] 0 0
Caba
Country [16] 0 0
Argentina
State/province [16] 0 0
Pergamino
Country [17] 0 0
Argentina
State/province [17] 0 0
Rosario
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussels
Country [19] 0 0
Belgium
State/province [19] 0 0
Yvoir
Country [20] 0 0
Brazil
State/province [20] 0 0
SP
Country [21] 0 0
Brazil
State/province [21] 0 0
Fortaleza
Country [22] 0 0
Brazil
State/province [22] 0 0
Salvador
Country [23] 0 0
Brazil
State/province [23] 0 0
Santo André
Country [24] 0 0
Brazil
State/province [24] 0 0
São Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
China
State/province [27] 0 0
Anhui
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Fujian
Country [30] 0 0
China
State/province [30] 0 0
Guangdong
Country [31] 0 0
China
State/province [31] 0 0
Hebei
Country [32] 0 0
China
State/province [32] 0 0
Hubei
Country [33] 0 0
China
State/province [33] 0 0
Hunan
Country [34] 0 0
China
State/province [34] 0 0
Jiangsu
Country [35] 0 0
China
State/province [35] 0 0
Jiangxi
Country [36] 0 0
China
State/province [36] 0 0
Jilin
Country [37] 0 0
China
State/province [37] 0 0
Liaoning
Country [38] 0 0
China
State/province [38] 0 0
Shandong
Country [39] 0 0
China
State/province [39] 0 0
Shanghai
Country [40] 0 0
China
State/province [40] 0 0
Sichuan
Country [41] 0 0
China
State/province [41] 0 0
Tianjin
Country [42] 0 0
China
State/province [42] 0 0
Zhejiang
Country [43] 0 0
China
State/province [43] 0 0
Hangzhou
Country [44] 0 0
Czechia
State/province [44] 0 0
Ostrava-Vitkovice
Country [45] 0 0
Czechia
State/province [45] 0 0
Plesice
Country [46] 0 0
Czechia
State/province [46] 0 0
Usti nad Labem
Country [47] 0 0
France
State/province [47] 0 0
Brest
Country [48] 0 0
France
State/province [48] 0 0
Dijon
Country [49] 0 0
France
State/province [49] 0 0
Lille
Country [50] 0 0
France
State/province [50] 0 0
Montpellier
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Rennes
Country [53] 0 0
France
State/province [53] 0 0
Saint Herblain
Country [54] 0 0
France
State/province [54] 0 0
Strasbourg
Country [55] 0 0
Germany
State/province [55] 0 0
Berlin
Country [56] 0 0
Germany
State/province [56] 0 0
Grosshansdorf
Country [57] 0 0
Germany
State/province [57] 0 0
Lowenstein
Country [58] 0 0
Germany
State/province [58] 0 0
Stolberg
Country [59] 0 0
Hong Kong
State/province [59] 0 0
Hong Kong
Country [60] 0 0
Hong Kong
State/province [60] 0 0
Sha Tin
Country [61] 0 0
Israel
State/province [61] 0 0
Be'er Sheva'
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Jerusalem
Country [64] 0 0
Israel
State/province [64] 0 0
Petah Tiqva
Country [65] 0 0
Israel
State/province [65] 0 0
Ramat Gan
Country [66] 0 0
Italy
State/province [66] 0 0
Aviano
Country [67] 0 0
Italy
State/province [67] 0 0
Legnago
Country [68] 0 0
Italy
State/province [68] 0 0
Meldola
Country [69] 0 0
Italy
State/province [69] 0 0
Milano
Country [70] 0 0
Italy
State/province [70] 0 0
Napoli
Country [71] 0 0
Italy
State/province [71] 0 0
Perugia
Country [72] 0 0
Italy
State/province [72] 0 0
Ravenna
Country [73] 0 0
Italy
State/province [73] 0 0
Rozzano
Country [74] 0 0
Italy
State/province [74] 0 0
Sondrio
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seoul
Country [76] 0 0
Netherlands
State/province [76] 0 0
Amsterdam
Country [77] 0 0
Netherlands
State/province [77] 0 0
Maastricht
Country [78] 0 0
Peru
State/province [78] 0 0
Lima
Country [79] 0 0
Poland
State/province [79] 0 0
Gdansk
Country [80] 0 0
Poland
State/province [80] 0 0
Warsaw
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Moscow
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Omsk
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Saint Petersburg
Country [84] 0 0
Spain
State/province [84] 0 0
Navarra
Country [85] 0 0
Spain
State/province [85] 0 0
Badajoz
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
Girona
Country [88] 0 0
Spain
State/province [88] 0 0
Madrid
Country [89] 0 0
Spain
State/province [89] 0 0
Palma de Mallorca
Country [90] 0 0
Turkey
State/province [90] 0 0
Edirne
Country [91] 0 0
Turkey
State/province [91] 0 0
Istanbul
Country [92] 0 0
Turkey
State/province [92] 0 0
Izmir
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Blackwood
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Bristol
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Nottingham
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Xcovery Holding Company, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary purpose of this study is to evaluate the efficacy and safety of X-396
(ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that
have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
Trial website
https://clinicaltrials.gov/show/NCT02767804
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications